Cargando…

Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia

BACKGROUND: Primary biliary cholangitis (PBC) is a progressive autoimmune cholestatic liver disease that primarily affects females more than males and may lead to end-stage liver disease. We studied baseline characteristics, and the biochemical and clinical response to ursodeoxycholic acid (UDCA), a...

Descripción completa

Detalles Bibliográficos
Autores principales:	AlWabel, Ahmed H, Peedikayil, Musthafa, AlNasser, Sulaiman, AlHusaini, Khalid, AlHekail, Othman, Alqahtani, Saleh A, AlTraif, Ibrahim H, AlAshgar, Hamad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270471/ https://www.ncbi.nlm.nih.gov/pubmed/35229756 http://dx.doi.org/10.4103/sjg.sjg_445_21

Ejemplares similares

Defecation of a “colon cast” as a rare presentation of acute graft-versus-host disease
por: Al Ashgar, Hamad, et al.
Publicado: (2009)

Retrospective Studies with Inconsistent Data: Results, Conclusions and Recommendations should be taken with a Grain of Salt
por: AlTraif, Ibrahim
Publicado: (2011)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia
por: Alsohaibani, Fahad, et al.
Publicado: (2020)

Prospective Trial in Saudi Arabia Comparing the 14-day Standard Triple Therapy with the 10-day Sequential Therapy for Treatment of Helicobacter Pylori Infection
por: Alsohaibani, Fahad, et al.
Publicado: (2015)

Wilson disease in 71 patients followed for over two decades in a tertiary center in Saudi Arabia: a retrospective review
por: Al Fadda, Mohammed, et al.
Publicado: (2012)

Response to: Treatment Prolongation or Quadruple Therapy:- Individualization by Geographical Region
por: Alsohaibani, Fahad, et al.
Publicado: (2016)

HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study
por: Al Ashgar, Hamad, et al.
Publicado: (2017)

Pancreatic cancer presenting with acute pancreatitis complicated by Wernicke’s encephalopathy and a colonic fistula: a case report
por: Ibnawadh, Abdulrahman K., et al.
Publicado: (2023)

Will any future increase in cigarette price reduce smoking in Saudi Arabia?
por: Al-Mohrej, Omar A., et al.
Publicado: (2014)

Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
por: Shu, Yanyun, et al.
Publicado: (2021)

Entecavir for the treatment of real-life chronic hepatitis B patients: a study from Saudi Arabia
por: Al-Ashqar, Hamad Ibrahim, et al.
Publicado: (2013)

Inflammatory bowel disease in Saudi Arabia: a hospital-based clinical study of 312 patients
por: Al Fadda, Mohammed, et al.
Publicado: (2012)

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018)

Levofloxacin-Based First-Line Therapy versus Standard First-Line Therapy for Helicobacter pylori Eradication: Meta-Analysis of Randomized Controlled Trials
por: Peedikayil, Musthafa Chalikandy, et al.
Publicado: (2014)

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
por: Cançado, Guilherme Grossi Lopes, et al.
Publicado: (2022)

Diminished accuracy of biomarkers of fibrosis in low replicative chronic hepatitis B
por: Sanai, Faisal M., et al.
Publicado: (2017)

Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis
por: Zimmer, Vincent, et al.
Publicado: (2016)

LBODP017 Unusual Presentation Of Brown Tumors In Tertiary Hyperparathyroidism: A Case-based Review
por: ALShehri, Sara Mohammed, et al.
Publicado: (2022)

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
por: Martinez-Gili, Laura, et al.
Publicado: (2023)

Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020)

The association between body mass index and frequency of emergency department visits and hospitalization for asthma exacerbation in a pediatric population
por: Alhekail, Ghadah Abdulrahman, et al.
Publicado: (2017)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis
por: Wang, Zi-Long, et al.
Publicado: (2022)

A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid
por: Li, Chunlei, et al.
Publicado: (2022)

Effects of gastric sleeve surgery on the serum levels of GH, IGF-1 and IGF-binding protein 2 in healthy obese patients
por: Al-Regaiey, Khalid, et al.
Publicado: (2020)

Recurrent Cholangitis Secondary to a Traumatic Biliary Neuroma
por: Rayyan, Nadin Y., et al.
Publicado: (2022)

Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials
por: Agrawal, Rohit, et al.
Publicado: (2019)

A 60-Year-Old Woman with Primary Biliary Cholangitis and Crohn’s Ileitis Following the Suspension of Ursodeoxycholic Acid
por: Romeo, Mario, et al.
Publicado: (2022)

Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
por: Ding, Dawei, et al.
Publicado: (2022)

Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion
por: Yang, Chunmei, et al.
Publicado: (2022)

Gastric Xanthomatosis Secondary to Lipoprotein X in Primary Biliary Cholangitis
por: Petrie, Erin, et al.
Publicado: (2022)

Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: A Retrospective Diagnosis
por: Al-Handola, Rami, et al.
Publicado: (2023)

Sphincterotomy with endoscopic biliary drainage for severe acute cholangitis: a meta-analysis
por: Sawas, Tarek, et al.
Publicado: (2017)

Inflammatory Fibroid Polyp of the Cecum can be Treated by Endoscopic Resection
por: Peedikayil, Musthafa Chalikandy, et al.
Publicado: (2008)

N-Butyl-2-Cyanoacrylate (Histoacryl) Complication: A Case Report
por: Al Ashgar, Hamad, et al.
Publicado: (2006)

Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis
por: Ni, Ping, et al.
Publicado: (2019)

Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease
por: Cortez‐Pinto, Helena, et al.
Publicado: (2021)

Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients
por: Wang, Zi-Long, et al.
Publicado: (2022)

Sustained Virologic Response to Peginterferon α-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center Experience
por: Al Ashgar, Hamad, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_aohlf18f7tsqenl2v5n7ca04q9